Inhibikase Therapeutics, Inc. develops clinical-stage protein kinase inhibitor therapeutics for cardiopulmonary disease, with IKT-001, an oral prodrug of imatinib mesylate, as its lead program for pulmonary arterial hypertension. Company news centers on the IMPROVE-PAH clinical program, FDA interactions, clinical-development milestones, and PAH biology involving Abelson tyrosine kinase, platelet-derived growth factor receptors and c-KIT.
Recurring updates also cover operating results, development spending, equity compensation under Nasdaq rules, common-stock and warrant financing activity, and leadership or commercial-planning changes tied to the PAH program.
Inhibikase Therapeutics has priced its initial public offering (IPO) at $10.00 per share, offering 1,800,000 shares and raising $18 million in gross proceeds. The shares will trade on the Nasdaq Capital Market under the ticker symbol IKT starting December 23, 2020, with the offering expected to close on December 28, 2020. The underwriters also have a 45-day option for an additional 270,000 shares. ThinkEquity serves as the sole book-running manager for the offering.